Multi-Mechanism Guidance and Personalization Engine (MMGPE): A Framework for Complex Disease Optimization and Pathway-Guided Drug Discovery

Abstract

Many chronic and heterogeneous diseases are driven by multiple interacting biological processes, yet both clinical care and therapeutic development are often organized around single-target paradigms. While reductionist approaches have generated important advances, they may be insufficient when parallel pathways sustain pathology, when patient subgroups differ biologically, or when existing regimens already partially cover selected targets. This paper is also available at: https://doi.org/10.5281/zenodo.19712359

Described here is the Multi-Mechanism Guidance and Personalization Engine (MMGPE), a general framework that evaluates disease as a network of relevant pathways, determines which mechanisms are already addressed, identifies residual gaps, and generates personalized optimization strategies.

The same framework can be extended across patient populations to identify recurring unmet pathway needs that may justify future therapeutic development. MMGPE is designed to be implementable as a manual worksheet, spreadsheet, software platform, or AI-enhanced system.

The framework is intended for complex disease states including neurodegeneration, autoimmune disease, cardiometabolic disorders, and other heterogeneous conditions.

Figure 1. Single-Target vs Multi-Mechanism Disease Model

Comparison of a single-pathway intervention versus a pathway-guided multi-domain optimization strategy in a disease sustained by multiple active mechanisms.

1. Introduction: Limits of Single-Target Thinking

Modern biomedical science has been highly successful in identifying molecular targets and designing therapies that modulate them. However, many chronic and heterogeneous diseases are not maintained by a single dominant mechanism. Instead, they arise from multiple interacting biological processes—including inflammation, vascular dysfunction, mitochondrial impairment, lipid dysregulation, proteostasis failure, excitotoxicity, oxidative stress, and immune dysregulation—that create self-reinforcing vicious cycles.

This multi-mechanistic reality creates several practical problems in both clinical care and therapeutic development:

1.     A therapy may successfully modulate one target while untreated parallel pathways continue to drive disease progression.

2.     Patients sharing the same diagnosis may differ substantially in dominant biology, leading to heterogeneous treatment responses.

3.     Existing regimens may already partially cover some mechanisms but leave others unaddressed, resulting in incomplete disease modification.

4.     Clinical failure of a single-pathway therapy does not necessarily imply that the targeted mechanism is irrelevant—only that it was insufficient in isolation.

5.     Drug discovery programs often prioritize biologically interesting targets without first confirming that those targets represent recurrent unmet needs in real-world patient populations.

These limitations are especially evident in complex conditions such as Alzheimer’s disease and related dementias (ADRD), autoimmune overlap syndromes, cardiometabolic disorders, and aging-related frailty. While frameworks such as the Bredesen ReCODE protocol have demonstrated the value of multi-factorial approaches in cognitive decline, there remains a need for a standardized, reusable, disease-agnostic framework that explicitly quantifies pathway coverage against any existing regimen, integrates ancestry-aware genetic data, and systematically links individual optimization to population-level gap discovery for future drug development.

The Multi-Mechanism Guidance and Personalization Engine (MMGPE) addresses this need by providing a structured, pathway-level lens for therapeutic decision-making and target prioritization.

2. The MMGPE Framework

The Multi-Mechanism Guidance and Personalization Engine (MMGPE) is a structured framework for pathway-aware therapeutic decision-making.

Figure 2. MMGPE Workflow

Illustrative framework showing patient data inputs, pathway coverage analysis, gap detection, personalization, population learning, and pathway-guided therapeutic discovery.

At its core, MMGPE includes five functional layers:

2.1 Pathway Representation Layer

A disease is represented as multiple relevant pathways or domains. Depending on indication, these may include:

·       inflammatory signaling

·       vascular biology

·       mitochondrial function

·       lipid handling

·       insulin/metabolic regulation

·       proteostasis

·       oxidative stress

·       excitotoxicity

·       microbiome-host signaling

·       fibrosis

·       immune regulation

2.2 Coverage Assessment Layer

Current interventions are mapped to pathways they may influence. These interventions may include:

·       prescription therapies

·       off-label therapies

·       OTC products

·       nutraceuticals

·       behavioral interventions

·       devices

·       environmental modifications

Each pathway can then be assessed as:

·       covered

·       partially covered

·       uncovered

2.3 Gap Identification Layer

Residual unmet mechanisms are identified after considering the existing regimen and patient context.

2.4 Personalization Layer

Priorities may be modified using patient-specific variables such as:

·       biomarkers

·       laboratory data

·       genetics

·       ancestry

·       family history

·       symptoms

·       tolerability

·       comorbidities

·       prior response history

·       practical constraints

2.5 Adaptive Learning Layer

As new data emerge over time, recommendations and pathway priorities can be updated.

3. Clinical Use Cases

3.1 Neurodegeneration

Conditions such as Alzheimer’s disease and related dementias (ADRD) are prototypical multi-mechanistic disorders. Recent multi-omics and network-medicine studies confirm convergence across amyloid-β metabolism, tau hyperphosphorylation, neuroinflammation/microglial activation, mitochondrial bioenergetic failure, lipid dysregulation, synaptic dysfunction, vascular impairment, proteostasis defects, oxidative stress, and excitotoxicity.

MMGPE in Action: Concrete ADRD ExampleConsider an older woman of 100% Asian ancestry with maternal family history of memory problems (suggesting possible mitochondrial contributions) and no major comorbidities. She is already receiving statin (lipid/pleiotropic anti-inflammatory), angiotensin receptor blocker (vascular/RAS protection), NAD+ (mitochondrial/sirtuins/autophagy), and microdose lithium (GSK3β/tau/autophagy/neuroprotection).

Applying the MMGPE framework yields the following standardized pathway table (adapted for clinical use):

Pathway / Biomarker	Mechanism	Notes on Genetic Predisposition	Coverage by Current Regimen
Amyloid-β Metabolism & Aggregation	APP cleavage, oligomer/plaque formation, impaired clearance	APOE ε4 impairs clearance; ancestry-specific loci (ABCA7, SORL1)	Partial (indirect via statin lipid effects)
Tau Hyperphosphorylation & Propagation	Kinase imbalance (GSK3β, CDK5), NFT formation	APOE ε4 promotes tau; MAPT variants; East Asian signals	Strong (lithium inhibits GSK3β + autophagy)
Neuroinflammation & Microglial Activation	NLRP3 inflammasome, cytokine release, complement	TREM2, LILRB2–LILRB5 (prominent in East Asian GWAS)	Partial (lithium + statin/ARB pleiotropic effects)
Mitochondrial Dysfunction	Impaired OXPHOS, ROS, mitophagy failure	Maternal mtDNA patterns; strong maternal history link	Strong (NAD+ restores pools & biogenesis)
Lipid Metabolism & Cholesterol Homeostasis	APOE-mediated transport, membrane rafts	APOE ε4 strongest risk (often pronounced effect size in East Asians/Filipinos)	Strong (Crestor)
Synaptic Dysfunction & Excitotoxicity	Synapse loss, glutamate dysregulation, calcium overload	Synaptic & ion-channel loci	Partial (supplement marginal)
Vascular & Cerebrovascular Dysfunction	Hypoperfusion, BBB breakdown, endothelial dysfunction	APOE ε4 + vascular genes; hypertension/diabetes interactions common in Filipinos	Strong (Losartan)
Proteostasis & Oxidative Stress	Autophagy/UPR failure, ROS/RNS damage	Autophagy & antioxidant gene variants	Partial (NAD+ + lithium promote autophagy)
Insulin/Metabolic Dysregulation	Brain insulin resistance	T2D-overlap genes; higher metabolic burden in Filipinos	Partial (indirect via existing agents)

Gap Analysis Output: Strong coverage exists in lipid, vascular, mitochondrial, and tau axes. Residual gaps include sustained microglial/immune resolution, excitotoxicity/glutamate homeostasis, and neurovascular/cGMP support.

Personalized Recommendations (ranked by mechanistic orthogonality, geriatric safety, and Delphi consensus signals):

·       High-priority: Low-dose sildenafil (cGMP/hemodynamic/tau modulation) or riluzole (excitotoxicity/glutamate).

·       OTC bridge: High-dose omega-3 (resolvin-mediated microglial resolution), bioavailable curcumin (NF-κB inhibition), and L-citrulline/beetroot nitrate (NO/cGMP vasodilation).

·       Monitoring: Repeat p-tau217, GFAP, cognitive testing, and ancestry-calibrated PRS refine weighting.

This example illustrates how MMGPE transforms a generic diagnosis into a precise, actionable multi-modal plan while highlighting opportunities for broader drug repurposing or development.

4. Drug Discovery Implications

MMGPE is not limited to optimizing existing care. It also provides a framework for identifying new therapeutic opportunities.

Across large patient populations, the same system can evaluate which pathways are repeatedly under-addressed despite current standard regimens. If a specific subgroup consistently demonstrates poor outcomes associated with an unmet pathway, that recurrent gap may justify targeted therapeutic development.

This creates a different R&D logic:

Traditional model:Choose a target → build a drug → test broadly

MMGPE model:Map unmet pathway needs in real patients → identify subgroup → prioritize target → develop therapy with precision enrollment strategy

This may improve translational efficiency by aligning target selection with real-world unmet biology.

5. Implementation Pathways

The framework may be implemented in multiple forms:

Manual Version

Printed worksheet or clinician checklist.

Spreadsheet Version

Structured scoring and prioritization.

Software Platform

Dashboard with patient-level outputs.

AI-Enhanced Version

Predictive ranking, simulations, and cohort learning.

Importantly, advanced AI is optional rather than foundational to the framework.

6. Future Directions

Potential future extensions include:

·       longitudinal digital twin models

·       biomarker-driven adaptive protocols

·       companion diagnostics

·       clinical trial enrichment systems

·       population-level therapeutic white-space mapping

·       integration with wearable and remote monitoring data

7. Conclusion

Many diseases are multi-mechanistic, yet treatment and therapeutic development are often still framed through single-target logic. The Multi-Mechanism Guidance and Personalization Engine (MMGPE) offers an alternative model: evaluate total pathway coverage, identify residual unmet needs, personalize intervention strategy, and use recurring gaps across populations to guide future drug development. This framework may be useful wherever disease complexity exceeds the explanatory power of one pathway alone.

References

1.     Corbett A, et al. Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation. Alzheimers Res Ther. 2025;17:237. doi:10.1186/s13195-025-015XX-X.

2.     Cao H, et al. Ethnic-specific effects of the LILRB2–LILRB5 locus and newly identified risk loci for Alzheimer’s disease in the East Asian population. Alzheimers Dement. 2026;22:e71219. doi:10.1002/alz.71219.

3.     Cardillo M, Katam K, Suravajhala P. Advancements in multi-omics research to address challenges in Alzheimer’s disease: a systems biology approach utilizing molecular biomarkers and innovative strategies. Front Aging Neurosci. 2025;17:1591796. doi:10.3389/fnagi.2025.1591796.

4.     Venkatesh S, et al. Integrative multi-omics approaches identify molecular pathways and improve Alzheimer’s disease risk prediction. Alzheimers Dement. 2025;21(11):e70886. doi:10.1002/alz.70886.

5.     Rao RV, et al. ReCODE: A Personalized, Targeted, Multi-Factorial Approach to Treating Alzheimer’s Disease. J Alzheimers Dis. 2021;84(4):1453–1465. doi:10.3233/JAD-210428.

6.     Hellmuth J. Can we trust The End of Alzheimer’s? Lancet Neurol. 2020;19(8):639–640. (Critical perspective on ReCODE protocol).

7.     Zhao Q, et al. Combined multi-omics and brain pathology reveal novel biomarkers for Alzheimer’s disease. Sci Rep. 2025;15:21983. doi:10.1038/s41598-025-21983-7.

8.     Johansson Å, et al. Precision medicine in complex diseases – Molecular and systems biology approaches. Mol Aspects Med. 2023;94:101214. doi:10.1016/j.mam.2023.101214.

9.     Jin L, et al. Pathway-based analysis tools for complex diseases: a review. Genomics. 2014;104(6 Pt B):433–442. doi:10.1016/j.ygeno.2014.08.011.

10.  Tran A, et al. Construction and optimization of multi-platform precision pathways. Sci Rep. 2024;14:54517. doi:10.1038/s41598-024-54517-8.